Hochschulschrift
Nanodose study of the CYP3A paradigm substrate midazolam to evaluate pharmacokinetic linearity of parent drug before and during CYP3A inhibition
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
21 cm
- Umfang
-
IX, 64 Bl.
- Sprache
-
Englisch
- Anmerkungen
-
graph. Darst.
Heidelberg, Univ., Diss., 2014
- Klassifikation
-
Medizin, Gesundheit
- Urheber
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:12 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Ähnliche Objekte (12)
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
Testing for co-non-linearity
Non-linearity of location factors
Linearity of the core correspondence
Linearity of holographic entanglement entropy
Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
Testing for co-non-linearity
Non-linearity of location factors
Linearity of the core correspondence
Linearity of holographic entanglement entropy
Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
Testing for co-non-linearity
Non-linearity of location factors
Linearity of the core correspondence
Linearity of holographic entanglement entropy
Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach